MAKETA 5/2 po
MAKETA 5/2 po
MAKETA 5/2 po
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
4<br />
A C T A M E D I C A M A R T I N I A N A 2 0 0 5 5/2<br />
METHODS<br />
Meconium<br />
Human meconium was collected from 20 healthy newborns, lyophilized, <strong>po</strong>oled and stored in<br />
–20 °C. Before use, meconium was suspended in 0.9 % NaCl at a concentration of 25 mg/ml.<br />
Surfactant<br />
Modified <strong>po</strong>rcine surfactant (Curosurf, Chiesi Pharmaceutici, Italy) was diluted in saline to<br />
a phospholipid concentration of 10 mg/ml.<br />
Design of experiments<br />
Experiments were carried out in concordance with the basic ethical norms and NIH Publication<br />
No. 86-23, revised 1985. Rabbits of the mean body weight (b.w.) of 2.0 kg were anesthetized<br />
with intramuscular ketamine (Narkamon, S<strong>po</strong>fa, Czech Republic) at a dose of 20 mg/kg b.w. and<br />
xylazine (Rometar, S<strong>po</strong>fa, Czech Republic) at a dose of 5 mg/kg b.w., followed by intravenous ketamine<br />
at a dose of 20 mg/kg b.w./hour. Animals were then tracheotomized, paralyzed with<br />
pipecuronium bromide (Arduan, Gedeon Richter, Hungary) at a dose of 0.3 mg/kg b.w./30 min<br />
i.v. and ventilated conventionally by pressure-controlled ventilator Beat-2 (Chirana, Slovakia)<br />
with frequency of 30/min. Meconium at a dose of 4 ml/kg b.w. was instilled pro<strong>po</strong>rtionally into<br />
the right and left lungs. Additional dose of meconium (25 mg/ml, 1 ml/kg b.w.) was given to animals<br />
not showing evidence of respiratory failure, defined as >30 % decrease in lung-thorax compliance<br />
and PaO 2<br />